



MEMORANDUM

TO: Community Pharmacies and PEI Pharmacists Association
FROM: PEI Biosimilar Initiative
DATE: January 4, 2024
SUBJECT: Biosimilar insulins and insulin pumps

A reminder that some patients may require continued access to an originator insulin because their insulin pump has not yet been approved for use with the biosimilar version of their insulin. Coverage of the originator insulin will be extended beyond the end of the switching period (June 30, 2024) if compatibility has not yet been confirmed.

- Pump and biosimilar insulin compatibility information was previously shared in a [PEI Pharmacare Memo](#) which can be found under the “Biosimilars” information on the [Resources for Pharmacists](#) page on the Health PEI Staff Resource Centre. It is also included below
- The Biosimilar Switching Exemption form can be used to identify patients who may require access to the Originator insulin beyond the end of the switching period (June 30, 2024). This form can be completed by the patient or health care professional and is available as an
 - [Online Biosimilar Switching Exemption form](#)
 - [Paper Biosimilar Switching Exemption form](#)
- Health Canada guidance on insulin product and pump compatibility claims can be found [here](#).

Biosimilar Insulin Compatibility with Continuous Subcutaneous Insulin Infusion (CSII) devices:

- **Medtronic (MiniMed 630G, 670G, 770G, 780G)**
 - Compatible: Admelog®
 - Not Compatible: Kirsty®, Trurapi®
- **Omnipod (Omnipod® Insulin Management System, Omnipod DASH® Insulin Management System)**
 - Compatible: Admelog®
 - Not Compatible: Kirsty®, Trurapi®
- **Tandem (t:slim X2 insulin pump)**
 - Compatible: Admelog®
 - Not Compatible: Kirsty®, Trurapi®

References:

1. *Insulin Pump Therapy*. Alberta Health Services and the Cumming School of Medicine. <https://cumming.ucalgary.ca/resources/endocrinology-metabolism/patients-and-family/diabetes/insulin-pump-therapy#biosimilar-insulins> (accessed December 22, 2023)
2. Medtronic. Canada Patient Letter Admelog and Extended infusion sets. Nov 2022. (Letter on file).
3. Medtronic. Canada Patient Letter Admelog and Extended infusion sets. May 2023. (Letter on file).
4. *Important safety information | Insulin Pump therapy | OmniPod*. <https://www.omnipod.com/en-ca/safety> (accessed December 22, 2023)
5. *t:slim X2 Insulin Pump | Type 1 Diabetes Insulin Pump | Tandem Diabetes Care*. (2023). Tandem Diabetes. <https://www.tandemdiabetes.com/en-ca/products/t-slim-x2-insulin-pump> (accessed December 22, 2023)

*** Information current at time of memo release. Please contact pump or insulin manufacturers for anticipated updates on compatibility or for pumps or models not included above.*

For further information about the PEI Biosimilar Initiative, please refer to:

- [PEI Biosimilar Initiative](#) webpage
- [Health PEI Staff Resource Centre Biosimilar information for health care professionals](#)
- Email: pei-biosimilar-initiative@gov.pe.ca
- Call: 902-218-4653